Tissue Adhesion, Surgery-Induced
Conditions
Keywords
Medicurtain®, Medicurtain, Anti-adhesion barrier, Sodium hyaluronate
Brief summary
This study was designed to demonstrate the non-inferiority of MEDICURTAIN® (investigational device) compared to commercially available GUARDIX-SG® (control device) in treatment of subject who underwent total thyroidectomy for prevention of adhesion formation at 6 weeks after the surgery.
Detailed description
This clinical trial is a randomized, multi center, subject and evaluator blinded, parallel, comparative and non-inferiority clinical trial study to assess the prevention of adhesion formation in the subjects treated either MEDICURTAIN® or GUARDIX-SG at 6 weeks after total thyroidectomy. The primary endpoint was defined as abnormal findings of esophageal motility evaluated by the independent third evaluator using marshmallow esophagography. The objective of this study was to demonstrate the non-inferiority of investigational device versus control device for adhesion formation at 6 weeks after the administration of investigational or control devices. Esophageal motility score and clinical symptoms assessed by the independent third evaluator using marshmallow esophagography at 6 weeks after administration of investigational device were secondary outcome.
Interventions
DEVICEGUARDIX-SG®
GUARDIX-SG® 6g prefilled syringe
DEVICEMedicurtain®
Medicurtain® 5ml prefilled syringe
Sponsors
Shin Poong Pharmaceutical Co. Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. The subject (male and female) aged between 20 \ 65. 2. The subject planned a first thyroidectomy for thyroid disease. 3. The subject did not have medical history of esophagus-related disease 4. The subject was suitable for local anesthesia or general anesthesia (Respiration and Intravenous anesthesia) 5. The subject who could communicate with the investigators fluently, understands the purpose of clinical trial and the risk of participation in the clinical trial, and was willing to comply with guideline for clinical trial. 6. The subject has been informed of the nature of the study (objective, methodology, efficacy, etc.) and signed written informed consent. 7. The subject has been informed the efficacy and risk of anesthesia related to the surgery, procedures and examination, etc. and singed written informed consent. 8. The subject who agrees to comply with permitted contraception during the study (example of permitted contraception: using condom and infertility surgery, etc.)
Exclusion criteria
1. The subject had general or local infection. 2. The subject was diagnosed with liver and/or kidney and coagulation abnormalities. 3. The subject took the prohibited concomitant medication. 4. The subject had suppressed immunity or autoimmune disease 5. The subject had hypersensitivity to the investigational devices. 6. The subject was pregnant of a nursing mother or those who plan pregnancy during the study. 7. The subject had serious disease that may affect to the study justified by Investigators (example: heart failure, kidney failure, pancreatitis, and diabetes, etc.) 8. The subjects participate in another investigational study after enrollment of this study or subject previously participated in another investigational study within last 3 months before participating in this study. 9. The subject considered to be not eligible to participate in the study justified by Investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presence of abnormal findings of esophageal motility evaluated by the independent third evaluator using marshmallow esophagography obtained at 6 weeks after administration of investigational device. | Week 6 | The percentage of abnormal findings measured as mild/moderate/severe in the esophageal motor performance score through marshmallow esophagography is the incidence of adhesion. The esophageal motility was scored as normal 3 point, mild 2 point, moderate 1 point and severe 0 point. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Esophageal motility score assessed by the independent third evaluator using marshmallow esophagography obtained at 6 weeks after administration of investigational device | Week 6 | The esophageal motility was scored as normal 3 point, mild 2 point, moderate 1 point and severe 0 point. |
| Clinical Symptoms assessed using questionnaire by investigator assessed by using 10 point visual analogue scale (VAS). | Follows up to week 6 | The questionnaire is composed of three questions as shown below. 1. Discomfort around surgical area 2. Discomfort when a patient bends his or her neck backward 3. Inflammation reaction and scar formation around surgical area Each item is evaluated in the 10-step evaluation of VAS. 0 = None of pain, 10 = Agonizing. |
| Clinical Symptoms assessed using questionnaire by subject assessed by using 10 point visual analogue scale (VAS). | Follows up to week 6 | The questionnaire is composed of four questions as shown below. 1. Difficulty in swallowing the saliva 2. Difficulty in swallowing the water 3. Difficulty in swallowing the solid food 4. Aesthetic self-satisfaction on the scar around surgical area Each item is evaluated in the 10-step evaluation of VAS. 0 = None of pain, 10 = Agonizing. |
Countries
South Korea
Outcome results
None listed